Why carry out this study?

Risankizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody inhibitor of interleukin (IL)-23 approved for treating moderate-to-severe plaque psoriasis. This study evaluated the efficacy and safety of directly switching patients who had prior suboptimal response to secukinumab or ixekizumab to risankizumab.

What was learned from this study?

Among patients with suboptimal response to secukinumab or ixekizumab, switching to risankizumab improved outcomes in patients at weeks 16 and 52.

In this difficult-to-treat group, where all patients had prior experience with biologics, 62.3% achieved clear/almost clear skin with risankizumab.

Switching to risankizumab without a washout period improved treatment outcomes in patients with prior suboptimal response to secukinumab or ixekizumab. The safety results were consistent with previously reported safety of risankizumab.